Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Matching-adjusted indirect comparisons of acalabrutinib vs ibrutinib in treatment-naïve CLL

Matthew Davids • 11 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Antibodies Ibrutinib
ELEVATE CLL R/R ELEVATE CLL TN RESONATE-2

Matthew Davids, MD, of the Dana-Farber Cancer Institute, Boston, MA, outlines data presented at EHA 2020 evaluating matched-adjusted indirect comparisons of efficacy and safety of acalabrutinib versus ibrutinib in treatment-naïve chronic lymphocytic leukemia (CLL) patients based on data collated from the ELEVATE CLL TN study (NCT02475681) as well as the RESONATE-2 study (NCT01722487). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Matthew Davids

Richter’s transformation: biology & ongoing trials in the field
Carsten Niemann et al. • 25 Mar 2024
1:53
CLL highlights from ASH 2023: the FLAIR study
Matthew Davids • 9 Dec 2023
2:15
CDK9 inhibition with voruciclib for treating AML and R/R B-cell NHL
Matthew Davids • 9 Dec 2023
1:21
Clinical characteristics and outcomes of the double refractory CLL/SLL patient population
Matthew Davids • 9 Dec 2023

Related Videos

1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals